|
| Investigators identified the protein Gibbin, encoded by the Xia–Gibbs AT-hook DNA-binding-motif-containing 1 disease gene as a key regulator of early epithelial morphogenesis. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| DERMAL STEM CELLS & TISSUE REGENERATION |
|
|
|
| In a mouse model of excisional skin wounding, inhibition or loss of solute carrier family 7 member 11 (SLC7A11) expression accelerated healing dynamics and reduced the apoptotic cell load in the wound. Mechanistic studies revealed a link between SLC7A11, glucose homeostasis, and diabetes. [Nature] |
|
|
|
| Keratinocyte migration and zebrafish tail regeneration experiments were used to evaluate the wound healing effect of a tocotrienol-based nanoemulsified system against ascorbic acid and phosphate-buffered saline as positive and negative controls, respectively. [PLoS One] |
| |
|
|
| Investigators successfully established subclones with various invasive potentials derived from human skin squamous carcinoma cells. [Oncogenesis] |
|
|
|
| The authors demonstrated that transcription factor Yin Yang 1 (YY1), while being essential for primary melanoma formation, suppressed metastatic spreading. [Frontiers in Cell and Developmental Biology] |
|
|
|
| Researchers revealed that eukaryotic initiation factor 6 (eIF6) was highly over-expressed in melanomas compared to normal skin specimens, and thus the abnormally high level of eIF6 could be a diagnostic marker for melanoma. [Frontiers in Oncology] |
|
|
|
| Analysis of the tumor suppressor gene growth arrest‑specific transcript 5 (GAS5) demonstrated that its expression was downregulated in melanoma, and its expression level had a certain negative association with its methylation modification level. [Oncology Reports] |
|
|
|
|
| The authors examine how microbiota-based mechanisms can be targeted to prevent or manage skin disorders and impaired wound healing. [Science] |
|
|
|
|
| RAPT Therapeutics, Inc. announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase IIb clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis. [RAPT Therapeutics, Inc.] |
|
|
|
|
Dermavant Sciences announced that the FDA has approved VTAMA® cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults. [Dermavant Sciences] |
| |
|
|
| November 7 – 8, 2022 London, England, United Kingdom |
|
|
|
|
|
| Oslo University Hospital – Oslo, Norway |
|
|
|
| University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| GSK – Collegeville, Pennsylvania, United States |
|
|
|
|
|